We are live on
!
Find out more
PCH
Polar Capital Holdings Portfolio holdings
AUM
$42.4B
1-Year Est. Return
181.11%
This Fund
S&P 500
This Quarter
Est. Return
-16.7%
1 Year Est. Return
+181.11%
3 Year Est. Return
+584.8%
5 Year Est. Return
+777.19%
10 Year Est. Return
–
AUM
$17B
AUM Growth
-$5.13B
(-23%)
Cap. Flow
-$794M
Cap. Flow
% of AUM
-4.67%
Top 10 Holdings %
Top 10 Hldgs %
43.02%
Holding
494
New
36
Increased
156
Reduced
156
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Salesforce
CRM
|
+$108M |
| 2 |
Visa
V
|
+$102M |
| 3 |
Mercado Libre
MELI
|
+$73M |
| 4 |
Enphase Energy
ENPH
|
+$58.6M |
| 5 |
Snowflake
SNOW
|
+$57.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$147M |
| 2 |
Y
Alleghany Corp
Y
|
+$137M |
| 3 |
Applied Materials
AMAT
|
+$116M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$115M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$111M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.66% |
| 2 | Industrials | 25.1% |
| 3 | Healthcare | 17.44% |
| 4 | Financials | 14.96% |
| 5 | Communication Services | 5.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
SolarEdge
SEDG
$2.17B
| $80.1M | 0.47% |
292,830
+83,240
| +40% | +$22.8M |
|
52
Steris
STE
$20.5B
| $78.2M | 0.46% |
379,349
-17,851
| -4% | -$4.02M |
|
53
Acadia Healthcare
ACHC
$2.64B
| $77.9M | 0.46% |
1,151,232
-21,507
| -2% | -$1.5M |
|
54
Xenon Pharmaceuticals
XENE
$5.64B
| $77.3M | 0.45% |
2,540,059
+350,000
| +16% | +$10.6M |
|
55
Neurocrine Biosciences
NBIX
$16B
| $76.5M | 0.45% |
784,287
+25,000
| +3% | +$2.31M |
|
56
Progressive
PGR
$126B
| $76.2M | 0.45% |
655,000
+45,750
| +8% | +$5.19M |
|
57
Everest Group
EG
$14.3B
| $75.7M | 0.44% |
270,000
+16,750
| +7% | +$4.73M |
|
|
58
Mercado Libre
MELI
$96.3B
| $75.1M | 0.44% |
117,843
+83,788
| +246% | +$73M |
|
59
Regeneron Pharmaceuticals
REGN
$81.7B
| $73.9M | 0.43% |
125,000
-20,000
| -14% | -$13M |
|
60
Elastic
ESTC
$8.94B
| $73M | 0.43% |
1,078,482
-60,709
| -5% | -$4.42M |
|
61
Incyte
INCY
$24.8B
| $72.3M | 0.42% |
951,040
-61,346
| -6% | -$4.66M |
|
62
United Therapeutics
UTHR
$21.3B
| $71.9M | 0.42% |
305,153
-68,227
| -18% | -$13.9M |
|
|
63
Enphase Energy
ENPH
$4.84B
| $69.9M | 0.41% |
358,235
+323,905
| +944% | +$58.6M |
|
64
Tenable Holdings
TENB
$3.86B
| $67M | 0.39% |
1,474,659
+13,759
| +0.9% | +$709K |
|
65
TripAdvisor
TRIP
$1.08B
| $66.6M | 0.39% |
3,740,029
-129,842
| -3% | -$3.08M |
|
66
Envista
NVST
$4.14B
| $63.8M | 0.37% |
1,655,656
+41,113
| +3% | +$1.73M |
|
67
Molina Healthcare
MOH
$11.2B
| $63.8M | 0.37% |
228,064
+22,341
| +11% | +$6.75M |
|
68
SiTime
SITM
$16.8B
| $63M | 0.37% |
386,496
+67,408
| +21% | +$12.7M |
|
69
CVS Health
CVS
$122B
| $62.9M | 0.37% |
678,970
-6,474
| -0.9% | -$632K |
|
70
Avantor
AVTR
$10.3B
| $62.8M | 0.37% |
2,018,178
+115,675
| +6% | +$3.61M |
|
71
Power Integrations
POWI
$2.92B
| $58.5M | 0.34% |
780,552
+123,912
| +19% | +$10.1M |
|
72
Zoom
ZM
$27.8B
| $57.3M | 0.34% |
530,666
+4,339
| +0.8% | +$458K |
|
73
Bio-Rad Laboratories Class A
BIO
$9.87B
| $57M | 0.33% |
115,059
+3,263
| +3% | +$1.7M |
|
74
First American
FAF
$7.33B
| $52.9M | 0.31% |
1,000,000
+412,500
| +70% | +$24M |
|
75
Johnson & Johnson
JNJ
$642B
| $51.6M | 0.3% |
290,575
-10,400
| -3% | -$1.85M |
|
Similar funds
GAM
SAM
Polar Capital Holdings's Q2 2022 Portfolio in Review
As of Q2 2022, Polar Capital Holdings held 494 positions worth $17B, down 23% from $22.2B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Polar Capital Holdings withdrew a net $794M in Q2 2022, closing 61 positions and reducing 156 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $147M position sold in full.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 33% a quarter earlier, followed by Industrials and Healthcare.
Against the trend, Polar Capital Holdings opened a new position in Sanofi worth $36.3M.
- Polar Capital Holdings's largest Q2 2022 buy was Sanofi: 725,000 shares worth $36.3M.
- Polar Capital Holdings added most to Salesforce in Q2 2022, an estimated $108M increase.
- Polar Capital Holdings's biggest Q2 2022 reduction was Applied Materials, cutting an estimated $116M.
- Polar Capital Holdings fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, selling an estimated $147M.
- Polar Capital Holdings's ten largest holdings make up 43% of its $17B portfolio in Q2 2022.
- Polar Capital Holdings opened 36 new positions and closed 61 in Q2 2022.
- Polar Capital Holdings's portfolio value fell 23% quarter-over-quarter to $17B.
Based on Polar Capital Holdings's 13F filing for Q2 2022, filed 15 Aug 2022.